| 產(chǎn)品編號(hào) | D51303 |
| 英文名稱 | AZD-9291 |
| 中文名稱 | |
| 別 名 | EGFR抑制劑 |
| 克 隆 號(hào) | |
| CAS | 1421373-65-0 |
| 理論分子量 | 499.61 kDa |
| 檢測分子量 | |
| 性 狀 | Lyophilized |
| 保存條件 | Store in dry, dark place for one year. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 產(chǎn)品介紹 |
AZD-9291, also known as Osimertinib and Mereletinib, is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines. AZD-9291 was approved in Nov. 2015 by FDA. |
